Article

Frequency-doubling technology threshold test effectiveness in detecting early glaucoma debate

Frequency-doubling technology (FDT) has a role as a diagnostic and monitoring instrument for glaucoma, although it may be best used to complement the use of other testing methods, particularly with the newer version of this technology. Studies suggest that the FDT may detect early glaucoma in a different subgroup of patients than other testing devices, and long-term studies will be needed to confirm its effectiveness in detection of progression.

Key Points

Atlanta-Frequency-doubling technology ([FDT] Carl Zeiss Meditec) perimetry was developed as a fast, effective method for detection of visual field loss. FDT was introduced in the late 1990s, and a second-generation instrument (Humphrey Matrix, Carl Zeiss Meditec) was released in 2005 with significant enhancements to its diagnostic capabilities. The consensus derived from numerous studies of the original FDT instrument was that it predicted the development of defects subsequently found with standard automated perimetry (SAP).

Describing the technology, he explained that, theoretically, conventional perimetry is nonselective, obtaining input from all the cell types in the layers of the retina, whereas FDT was designed to preferentially stimulate only a subset of retinal ganglion cells in the magnocellular (M-cell) pathway. FDT capitalizes on the fact that the M-cell pathway is involved in the detection of motion. Patterns of flickering black-and-white bars incite a reaction in these cells and create the perception that twice as many bars are present. It is believed that a group of M-cells, the My cells, are lost in early glaucoma and that, therefore, the frequency doubling illusion could be a useful diagnostic tool. The degree of isolation of this pathway is a matter of debate, however, Dr. Girkin said.

A 2008 study by Racette et al. showed that the 24-2 FDT threshold test, introduced with the second-generation FDT instrument, performed similarly in tests of visual function to the first-generation FDT N-30 test. The study also demonstrated that the FDT 24-2 was better than SAP at discriminating between healthy and glaucomatous eyes.

Additional studies, however, have not clearly demonstrated greater sensitivity for the FDT over SAP using a newer algorithm (Swedish Interactive Threshold Algorithm [SITA], Carl Zeiss Meditec) strategy.

"What is interesting is that these tests appear to be identifying abnormal visual function in a different subset of eyes with early glaucoma," Dr. Girkin said.

Emerging evidence also hints that using FDT could be advantageous in following damaged regions for progression. Two studies have shown that test-retest variability in 24-2 FDT is lower in damaged areas, likely due to a larger region of sampling with the FDT stimuli.

In a clinical setting, the FDT 24-2 may complement the use of the newer algorithm with SAP in determining whether eyes with suspicious-appearing optic nerves truly have early glaucoma, he said. Corroboration of FDT results with repeat testing and with optic nerve structure, however, is required to rule out false positives.

FDT 24-2 has promising characteristics that may help in the detection of progression, Dr. Girkin continued, but longitudinal data are needed to define its relative efficacy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.